POS0781 EFFICACY AND SAFETY OF ORAL DEUCRAVACITINIB IN PATIENTS WITH CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS: RESULTS FROM PAISLEY CLE, A GLOBAL, RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIALJ.F. Merola, V.P. Werth, Jürgen J. Wenzel et al.|Annals of the Rheumatic Diseases|2025Cited by 5
LP-180 Design of a phase 2, double-blind, placebo-controlled, global trial of deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with active discoid and/or subacute cutaneous lupus erythematosusVictoria P. Werth, Shimon Korish, Joseph F. Merola et al.|Unknown|2023Cited by 0